Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.

Stahler A, Heinemann V, Neumann J, Crispin A, Schalhorn A, Stintzing S, Giessen-Jung C, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Holch JW, Kruger S, Haas M, Michl M, von Einem J, Kirchner T, Jung A, Modest DP.

Anticancer Drugs. 2017 Aug;28(7):717-722. doi: 10.1097/CAD.0000000000000510.

PMID:
28582279
2.

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).

Stahler A, Heinemann V, Giessen-Jung C, Crispin A, Schalhorn A, Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Held S, von Einem JC, Holch J, Neumann J, Kirchner T, Jung A, Modest DP.

Int J Cancer. 2016 Feb 1;138(3):739-46. doi: 10.1002/ijc.29807. Epub 2015 Sep 18.

3.

[Leukemia].

Schalhorn A.

MMW Fortschr Med. 2013 Nov 7;155(19):48-52; quiz 53. Review. German. No abstract available.

PMID:
24475671
4.

Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).

Modest DP, Schulz C, von Weikersthal LF, Quietzsch D, von Einem JC, Schalhorn A, Vehling-Kaiser U, Laubender RP, Giessen C, Stintzing S, Heinemann V.

Anticancer Drugs. 2014 Feb;25(2):212-8. doi: 10.1097/CAD.0000000000000041.

PMID:
24201305
5.

Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.

Giessen C, Fischer von Weikersthal L, Laubender RP, Stintzing S, Modest DP, Schalhorn A, Schulz C, Heinemann V.

Br J Cancer. 2013 Sep 17;109(6):1428-36. doi: 10.1038/bjc.2013.475. Epub 2013 Aug 20.

6.

Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial.

Giessen C, Laubender RP, Fischer von Weikersthal L, Schalhorn A, Modest DP, Stintzing S, Haas M, Mansmann UR, Heinemann V.

Cancer Sci. 2013 Jun;104(6):718-24. doi: 10.1111/cas.12148. Epub 2013 Apr 15.

7.

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo JR, Lopez-Vivanco G, Adler G, Canon JL, Lofts F, Castanon C, Fonseca E, Rixe O, Aparicio J, Cassinello J, Nicolson M, Mousseau M, Schalhorn A, D'Hondt L, Kerger J, Hossfeld DK, Garcia Giron C, Rodriguez R, Schoffski P, Misset JL.

Br J Cancer. 2012 Jul 24;107(3):435-41. doi: 10.1038/bjc.2012.286. Epub 2012 Jul 5.

8.

Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.

van Kuilenburg AB, Häusler P, Schalhorn A, Tanck MW, Proost JH, Terborg C, Behnke D, Schwabe W, Jabschinsky K, Maring JG.

Clin Pharmacokinet. 2012 Mar 1;51(3):163-74. doi: 10.2165/11595880-000000000-00000.

PMID:
22339448
9.

Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.

Giessen C, Stintzing S, Laubender RP, Ankerst DP, Schulz C, Moosmann N, Modest DP, Schalhorn A, von Weikersthal LF, Heinemann V.

Clin Colorectal Cancer. 2011 Dec;10(4):317-24. doi: 10.1016/j.clcc.2011.03.027. Epub 2011 May 12.

PMID:
21729676
10.

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V.

J Clin Oncol. 2011 Mar 10;29(8):1050-8. doi: 10.1200/JCO.2010.31.1936. Epub 2011 Feb 7.

PMID:
21300933
11.

Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.

Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach PA, Lambertz H, Oruzio D, Schlag R, Weigang-Köhler K, Vehling-Kaiser U, Schulze M, Truckenbrodt J, Goebeler M, Mittermüller J, Bosse D, Szukics B, Grundeis M, Zwingers T, Giessen C, Heinemann V.

Eur J Cancer. 2011 Jan;47(2):206-14. doi: 10.1016/j.ejca.2010.09.022.

PMID:
20971632
12.

UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.

Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, Stemmler HJ.

World J Gastroenterol. 2009 Oct 28;15(40):5058-66.

13.

Diagnostic relevance of circulating biomarkers in patients with lung cancer.

Molina R, Holdenrieder S, Auge JM, Schalhorn A, Hatz R, Stieber P.

Cancer Biomark. 2010;6(3-4):163-78. doi: 10.3233/CBM-2009-0127. Review.

PMID:
20660962
14.

Tissue levels of reduced folates in patients with colorectal carcinoma after infusion of folinic acid at various dose levels.

Schlemmer M, Kuehl M, Schalhorn A, Rauch J, Jauch KW, Hentrich M.

Clin Cancer Res. 2008 Dec 1;14(23):7930-4. doi: 10.1158/1078-0432.CCR-08-0258.

15.

Clinical relevance of circulating nucleosomes in cancer.

Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von Pawel J, Raith H, Feldmann K, Kremer AE, Müller S, Geiger S, Hamann GF, Seidel D, Stieber P.

Ann N Y Acad Sci. 2008 Aug;1137:180-9. doi: 10.1196/annals.1448.012. Review.

PMID:
18837945
16.

Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma.

Christopeit M, Lenz G, Forstpointner R, Bartelheim K, Kühnbach R, Naujoks K, Schalhorn A.

Chemotherapy. 2008;54(4):309-14. doi: 10.1159/000151352. Epub 2008 Aug 14.

PMID:
18701819
17.

Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene.

van Kuilenburg AB, Maring JG, Schalhorn A, Terborg C, Schmalenberg H, Behnke D, Schwabe W, Jabschinsky K, Hausler P.

Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):692-8. doi: 10.1080/15257770802145009.

PMID:
18600527
18.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.

J Clin Oncol. 2006 Aug 20;24(24):3946-52.

PMID:
16921047
19.

Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments.

Mueller S, Holdenrieder S, Stieber P, Haferlach T, Schalhorn A, Braess J, Nagel D, Seidel D.

BMC Cancer. 2006 May 30;6:143.

20.

A new concurrent chemotherapy with vinorelbine and mitomycin C in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.

Wilkowski R, Pachmann S, Schymura B, Dellian M, Schalhorn A, Dühmke E.

Onkologie. 2005 Oct;28(10):491-5. Epub 2005 Aug 2.

PMID:
16160398
21.

[Tumor markers--how they should be applied].

Stieber P, Heinemann V, Schalhorn A.

MMW Fortschr Med. 2005 May 19;147(20):35, 37-9. German.

PMID:
15957858
22.

Metastasis of a rectal adenocarcinoma to the thyroid gland: diagnostic and therapeutic implications.

Hacker U, Lenz G, Brehm G, Müller-Höcker J, Schalhorn A, Hiddemann W.

Anticancer Res. 2003 Nov-Dec;23(6D):4973-6.

PMID:
14981954
23.

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?

Stemmler J, Stieber P, Szymala AM, Schalhorn A, Schermuly MM, Wilkowski R, Helmberger T, Lamerz R, Stoffregen C, Niebler K, Garbrecht M, Heinemann V.

Onkologie. 2003 Oct;26(5):462-7.

PMID:
14605463
24.

Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution.

Lenz G, Hacker UT, Kern W, Schalhorn A, Hiddemann W.

Anticancer Drugs. 2003 Oct;14(9):731-3.

PMID:
14551506
25.

Detrimental immunologic effects of preoperative chemoradiotherapy in advanced rectal cancer.

Wichmann MW, Meyer G, Adam M, Höchtlen-Vollmar W, Angele MK, Schalhorn A, Wilkowski R, Müller C, Schildberg FW.

Dis Colon Rectum. 2003 Jul;46(7):875-87.

PMID:
12847360
26.

Castleman's disease causing obstructive jaundice.

Przkora R, Bruns C, Zülke C, Heinkelein J, Rümmele P, Schalhorn A, Jauch KW.

J Hepatol. 2003 Apr;38(4):548-9. No abstract available.

PMID:
12663253
27.

Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases.

Stemmler J, Heinemann V, Schalhorn A.

Onkologie. 2002 Apr;25(2):182-4.

PMID:
12006771
28.

[Modern chemotherapy in bronchial carcinoma].

Schalhorn A.

Internist (Berl). 2002 Mar;43(3):416-30. Review. German. No abstract available.

PMID:
11963726
29.

Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure.

Stemmler J, Weise A, Hacker U, Heinemann V, Schalhorn A.

Onkologie. 2002 Feb;25(1):60-3.

PMID:
11893885
30.

Circulating nucleosomes in serum.

Holdenrieder S, Stieber P, Bodenmüller H, Busch M, Von Pawel J, Schalhorn A, Nagel D, Seidel D.

Ann N Y Acad Sci. 2001 Sep;945:93-102. Review.

PMID:
11708501
31.

[Pronounced osteoporosis, shrunken stature and blue coloration of sclerae in a 47-year old patient].

Lang NK, Schalhorn A, Hiddemann W.

Internist (Berl). 2001 Aug;42(8):1151-5. German. No abstract available.

PMID:
11556110
32.

Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer.

Kern W, Beckert B, Lang N, Stemmler J, Beykirch M, Stein J, Goecke E, Waggershauser T, Braess J, Schalhorn A, Hiddemann W.

Ann Oncol. 2001 May;12(5):599-603.

PMID:
11432616
33.
34.

Nucleosomes in serum of patients with benign and malignant diseases.

Holdenrieder S, Stieber P, Bodenmüller H, Busch M, Fertig G, Fürst H, Schalhorn A, Schmeller N, Untch M, Seidel D.

Int J Cancer. 2001 Mar 20;95(2):114-20. Erratum in: Int J Cancer 2001 Nov 20;95(6):398.

35.

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer.

Heinemann V, Wilke H, Mergenthaler HG, Clemens M, König H, Illiger HJ, Arning M, Schalhorn A, Possinger K, Fink U.

Ann Oncol. 2000 Nov;11(11):1399-403.

PMID:
11142479
36.

[Percutaneous implantation of port-catheter systems for intraarterial chemotherapy of the liver].

Waggershauser T, Herrmann K, Schalhorn A, Reiser M.

Radiologe. 1999 Sep;39(9):772-6. German.

PMID:
10525635
37.

Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.

Seemann MD, Seemann O, Dienemann H, Schalhorn A, Prime G, Fink U.

Eur J Med Res. 1999 Aug 25;4(8):313-27.

PMID:
10471543
38.

Apoptosis in serum of patients with solid tumours.

Holdenrieder S, Stieber P, Förg T, Kühl M, Schulz L, Busch M, Schalhorn A, Seidel D.

Anticancer Res. 1999 Jul-Aug;19(4A):2721-4.

PMID:
10470228
39.

Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.

Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, Yamaguchi K.

Anticancer Res. 1999 Jul-Aug;19(4A):2673-8.

PMID:
10470218
40.

CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.

Hasholzner U, Stieber P, Reiter W, Zimmermann A, Hofmann K, Schalhorn A.

Anticancer Res. 1999 Jul-Aug;19(4A):2477-80.

PMID:
10470177
41.

CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin.

Heinemann V, Schermuly MM, Stieber P, Schulz L, Jüngst D, Wilkowski R, Schalhorn A.

Anticancer Res. 1999 Jul-Aug;19(4A):2433-5.

PMID:
10470171
42.

Nuclear mitotic apparatus protein (NuMA) in benign and malignant diseases.

Hasholzner U, Stieber P, Zimmermann A, Burges A, Hofmann K, Schmitt UM, Schmeller N, Schalhorn A.

Anticancer Res. 1999 Jul-Aug;19(4A):2415-20.

PMID:
10470168
43.

[Recommendations on contents of medical reports in rectal carcinoma: III: Radiotherapy report and final report of chemotherapy. Orientation aids in interdisciplinary patient management].

Engel J, Feldmann HJ, Bayerl A, Rohloff R, Skulina E, Sauer H, Schalhorn A, Jauch KW.

Zentralbl Chir. 1998;123(12):1436-8. German. No abstract available.

PMID:
10063559
44.

Renal complications in acute leukemias.

Munker R, Hill U, Jehn U, Kolb HJ, Schalhorn A.

Haematologica. 1998 May;83(5):416-21.

45.

[50-year-old patient with left-sided inguinal pain].

Szukics B, Gerl A, Lamerz R, Arnoldt H, Schalhorn A.

Internist (Berl). 1998 Feb;39(2):202-7. German. No abstract available.

PMID:
9556734
46.

Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.

Wendt TG, Grabenbauer GG, Rödel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A.

J Clin Oncol. 1998 Apr;16(4):1318-24.

PMID:
9552032
47.

[54-year-old, severely ill patient with diffuse pain syndrome, peripheral facial paralysis and progressive tetraparesis].

Duell T, Schalhorn A, Pötscher C, Haberl C, Beykirch M, Pfister W, Wilmanns W.

Internist (Berl). 1996 Aug;37(8):839-43. German. No abstract available.

PMID:
8964676
48.

[Young man with swelling of the left side of the neck and right testis].

Jakob AR, Kühl M, Wilmanns W, Schalhorn A.

Internist (Berl). 1995 Nov;36(11):1080-4. German. No abstract available.

PMID:
8543445
49.

Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure.

Zoubek A, Zaunschirm HA, Lion T, Fischmeister G, Vollnhofer G, Gadner H, Pillwein K, Schalhorn A, Bode U.

Pediatr Hematol Oncol. 1995 Sep-Oct;12(5):471-7.

PMID:
8519632
50.

[Pharmacology of regional chemotherapy of colorectal liver metastases].

Schalhorn A, Kühl M.

Zentralbl Chir. 1995;120(10):764-8. Review. German.

PMID:
7502590

Supplemental Content

Loading ...
Support Center